Home Tags Investments

Tag: Investments

Gearing Up to be In the Center of ADC Development

Following intensified investments, new partnerships, out-licensing ADC assets, and major scientific advances from companies including Bristol Myers Squibb (a US $8.4 billion deal with SystImmune), AstraZeneca (the company signed a US $ 600 million dollar deal to obtain global from LaNova Medicines for pre-clinical ADC candidates), Roche, Lonza, MilliporeSigma, BioNTech (acquired 2 different ADC assets from DualityBio for an upfront payment of US $170 million. The company also obtained a novel ADC HER3 assets from MediLink Therapeutics), Myricx Bio (licensed rights to an antibody discovered by WuXi Biologics),  while GlaxoSmithKline (acquired ex-China rights for B7-H4 ADC from Hansoh Pharma in a $1.57 billion deal, plus royalties on sales), and others, China is expected to drive the next research boom in novel, innovative medicines, like antibody-drug conjugates (ADC).

Novo Holdings to Acquire Catalent

Novo Holdings, the holding and investment company managing the assets of the Novo Nordisk Foundation, an enterprise foundation with philanthropic objectives founded in Denmark in 1924.  The holding company, which is also the controlling shareholder of Novo Nordisk and Novonesis, has agreed to acquire all outstanding shares of Catalent*, a CDMO working with pharma and biotech partners to optimize product development, launch, and full life-cycle supply for patients around the world.